• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床前非酒精性脂肪肝研究中治疗前肝活检的可行性和稳定性。

Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies.

机构信息

Department Translational Medicine, Hanyang University Graduate School of Biomedical Science and Engineering, Seoul, Korea.

Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.

出版信息

J Korean Med Sci. 2019 Jan 3;34(2):e14. doi: 10.3346/jkms.2019.34.e14. eCollection 2019 Jan 14.

DOI:10.3346/jkms.2019.34.e14
PMID:30636945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6327092/
Abstract

BACKGROUND

The heterogeneity of histological findings in preclinical diet-induced nonalcoholic fatty liver disease (NAFLD) animal models is highly challenging. Here, we aimed to evaluate the feasibility and stability of repeated liver biopsy in NAFLD animal models.

METHODS

Heterogeneity of diet-induced NAFLD was evaluated at different time points in 52 high-fat diet (HFD), 35 methionine choline-deficiency diet (MCD), and 166 western diet (WD) induced NAFLD mice. Serial liver biopsies (left lateral, right medial, and left medial lobes) were performed monthly for up to 3 months. Mortality rates and changes in food intake, body weight, and liver enzymes were assessed.

RESULTS

At 12 weeks, of the HFD animals, 14% and 30% did not develop steatosis and lobular inflammation, respectively; of the MCD animals, 7% did not develop lobular inflammation; and of the WD animals, 14% and 51% did not develop steatosis and lobular inflammation, respectively. The mortality rate of repeated liver biopsy was 1.62% (2/123 mice died). Repeated liver biopsy can be used to trace disease progression. Although body weight, food intake, and liver enzymes slightly changed after biopsy, all recovered within a week. Repeated liver biopsy did not affect the degrees of inflammation and steatosis of the other liver lobes.

CONCLUSION

The diet-induced NAFLD models were quite heterogeneous. Our results suggest that the repeated liver biopsy before treatment was applicable and stable in this NAFLD animal study.

摘要

背景

临床前饮食诱导非酒精性脂肪性肝病(NAFLD)动物模型的组织学表现存在很大的异质性。本研究旨在评估 NAFLD 动物模型中重复肝活检的可行性和稳定性。

方法

在 52 只高脂肪饮食(HFD)、35 只蛋氨酸胆碱缺乏饮食(MCD)和 166 只西方饮食(WD)诱导的 NAFLD 小鼠中,不同时间点评估饮食诱导的 NAFLD 的异质性。每月进行 3 次重复肝活检(左外侧、右内侧和左内侧叶),持续 3 个月。评估死亡率以及食物摄入量、体重和肝酶的变化。

结果

在 12 周时,HFD 动物中分别有 14%和 30%的动物未发生脂肪变性和肝小叶炎症;MCD 动物中分别有 7%和 93%的动物未发生肝小叶炎症;WD 动物中分别有 14%和 51%的动物未发生脂肪变性和肝小叶炎症。重复肝活检的死亡率为 1.62%(123 只小鼠中有 2 只死亡)。重复肝活检可用于追踪疾病进展。尽管活检后体重、食物摄入量和肝酶略有变化,但均在一周内恢复。重复肝活检不会影响其他肝叶的炎症和脂肪变性程度。

结论

饮食诱导的 NAFLD 模型存在较大异质性。本研究结果表明,在该 NAFLD 动物研究中,治疗前重复肝活检是可行且稳定的。

相似文献

1
Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies.临床前非酒精性脂肪肝研究中治疗前肝活检的可行性和稳定性。
J Korean Med Sci. 2019 Jan 3;34(2):e14. doi: 10.3346/jkms.2019.34.e14. eCollection 2019 Jan 14.
2
A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.高脂肪饮食和蛋氨酸-胆碱缺乏饮食动物模型中非酒精性脂肪性肝病基因表达谱的比较。
Molecules. 2022 Jan 27;27(3):858. doi: 10.3390/molecules27030858.
3
Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.比较非酒精性脂肪性肝病小鼠模型和患者肝组织的基因表达谱。
Gastroenterology. 2016 Sep;151(3):513-525.e0. doi: 10.1053/j.gastro.2016.05.051. Epub 2016 Jun 16.
4
Evaluation of Nonalcoholic Fatty Liver Disease in C57BL/6J Mice by Using MRI and Histopathologic Analyses.使用磁共振成像(MRI)和组织病理学分析评估C57BL/6J小鼠的非酒精性脂肪性肝病
Comp Med. 2015 Oct;65(5):409-15.
5
The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.FATZO小鼠是2型糖尿病的下一代模型,在喂食添加了果糖的西式饮食时会发展为非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)。
BMC Gastroenterol. 2019 Mar 18;19(1):41. doi: 10.1186/s12876-019-0958-4.
6
The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.全氟辛烷酸对高脂饮食诱导的小鼠非酒精性脂肪性肝病的影响。
Toxicology. 2019 Mar 15;416:1-14. doi: 10.1016/j.tox.2019.01.017. Epub 2019 Jan 31.
7
Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.维生素 D 受体靶向肝细胞核因子 4α 并介导维生素 D 在非酒精性脂肪性肝病中的保护作用。
J Biol Chem. 2020 Mar 20;295(12):3891-3905. doi: 10.1074/jbc.RA119.011487. Epub 2020 Feb 12.
8
Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.在小鼠的高脂肪-高胆固醇-高糖饮食模型中,非酒精性脂肪变性进展为脂肪性肝炎和肝纤维化与促进炎症和肝肿瘤的危险信号的累积平行。
J Transl Med. 2015 Jun 16;13:193. doi: 10.1186/s12967-015-0552-7.
9
Prophylactic and therapeutic effects of different doses of vitamin C on high-fat-diet-induced non-alcoholic fatty liver disease in mice.不同剂量维生素 C 对高脂饮食诱导的非酒精性脂肪肝病小鼠的预防和治疗作用。
Biomed Pharmacother. 2020 Nov;131:110792. doi: 10.1016/j.biopha.2020.110792. Epub 2020 Sep 30.
10
Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.牙龈卟啉单胞菌参与非酒精性脂肪性肝病的进展。
J Gastroenterol. 2018 Feb;53(2):269-280. doi: 10.1007/s00535-017-1368-4. Epub 2017 Jul 24.

引用本文的文献

1
Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids.基于生物标志物的非酒精性脂肪性肝炎中皂苷治疗优化:从小鼠模型到人类肝脏类器官
Antioxidants (Basel). 2025 Jul 31;14(8):943. doi: 10.3390/antiox14080943.
2
Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.替格瑞洛可减轻代谢相关脂肪性肝病模型中的肝脂肪变性,而氯吡格雷则无此作用。
Nutrients. 2024 Mar 22;16(7):920. doi: 10.3390/nu16070920.
3
Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease.

本文引用的文献

1
Estimated Prevalence of Adolescents with Nonalcoholic Fatty Liver Disease in Korea.韩国青少年非酒精性脂肪性肝病的患病率估计。
J Korean Med Sci. 2018 Apr 2;33(14):e109. doi: 10.3346/jkms.2018.33.e109.
2
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.利拉鲁肽、奥贝胆酸和 Elafibranor 在经活检证实的非酒精性脂肪性肝炎肥胖小鼠模型中的代谢和肝脏作用。
World J Gastroenterol. 2018 Jan 14;24(2):179-194. doi: 10.3748/wjg.v24.i2.179.
3
Preclinical models of non-alcoholic fatty liver disease.
发现生物标志物以优化奥贝胆酸治疗非酒精性脂肪性肝病。
Biol Direct. 2023 Aug 25;18(1):50. doi: 10.1186/s13062-023-00407-4.
4
Establishment of repeated liver biopsy technique in experimental mice.实验小鼠重复肝脏活检技术的建立
Heliyon. 2023 Jun 3;9(6):e16978. doi: 10.1016/j.heliyon.2023.e16978. eCollection 2023 Jun.
5
Correlation between cholecystectomy and development of non-alcoholic liver disease in the mouse model.小鼠模型中胆囊切除术与非酒精性肝病发生之间的相关性。
Ann Transl Med. 2022 Aug;10(15):814. doi: 10.21037/atm-21-5414.
6
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial.使用改良的篮式试验在非酒精性脂肪性肝病小鼠模型中发现二肽基肽酶-4 抑制剂的特异性生物标志物。
Clin Mol Hepatol. 2022 Jul;28(3):497-509. doi: 10.3350/cmh.2022.0019. Epub 2022 Apr 28.
7
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.活检证实的非酒精性脂肪性肝炎(NASH)肥胖小鼠模型中基于活检的药物疗效的有效性。
BMC Gastroenterol. 2019 Dec 28;19(1):228. doi: 10.1186/s12876-019-1149-z.
非酒精性脂肪性肝病的临床前模型。
J Hepatol. 2018 Feb;68(2):230-237. doi: 10.1016/j.jhep.2017.10.031. Epub 2017 Nov 9.
4
Mouse models of nonalcoholic steatohepatitis in preclinical drug development.非酒精性脂肪性肝炎的小鼠模型在临床前药物研发中的应用。
Drug Discov Today. 2017 Nov;22(11):1707-1718. doi: 10.1016/j.drudis.2017.06.007. Epub 2017 Jul 4.
5
Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.奥贝胆酸可改善小鼠饮食性肥胖而非代谢性肥胖中的脂肪形态和炎症,并减轻脂肪变性。
Obesity (Silver Spring). 2017 Jan;25(1):155-165. doi: 10.1002/oby.21701. Epub 2016 Nov 2.
6
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.通过肝活检追踪非酒精性脂肪性肝炎疾病的肥胖饮食诱导小鼠模型。
World J Hepatol. 2016 Jun 8;8(16):673-84. doi: 10.4254/wjh.v8.i16.673.
7
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.依洛前列素,一种过氧化物酶体增殖物激活受体-α和-δ激动剂,可在不加重肝纤维化的情况下诱导非酒精性脂肪性肝炎消退。
Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.
8
MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.高脂饮食诱导的非酒精性脂肪性肝病-非酒精性脂肪性肝炎-肝细胞癌进展中的微小RNA表达分析:对C57BL/6J小鼠的研究
BMC Cancer. 2016 Jan 5;16:3. doi: 10.1186/s12885-015-2007-1.
9
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.利拉鲁肽治疗非酒精性脂肪性肝炎(LEAN)患者的安全性和有效性:一项多中心、双盲、随机、安慰剂对照的 2 期研究。
Lancet. 2016 Feb 13;387(10019):679-690. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20.
10
Histologic and Metabolic Derangement in High-Fat, High-Fructose, and Combination Diet Animal Models.高脂、高果糖及联合饮食动物模型中的组织学和代谢紊乱
ScientificWorldJournal. 2015;2015:306326. doi: 10.1155/2015/306326. Epub 2015 May 18.